Acceptance based on objective response rate data from the Phase 2 LITESPARK-015 trial evaluating WELIREG in certain patients with advanced PPGL If approved, WELIREG would be the only available therapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback